Home/ Stocks/ URGN

UroGen Pharma Ltd. Ordinary Shares

URGN XNAS

$46.96 +1.36 (+2.98%) ▲ 15-min delayed

Open

$47.23

High

$48.19

Low

$45.75

Volume

1.03M

Market Cap

$2.22B

About UroGen Pharma Ltd. Ordinary Shares

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 291 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$72.46M	$-14,351,000	$-0.28
Q1 2026	$50.96M	$-23,574,000	$-0.47
FY 2025	$109.79M	$-153,494,000	$-3.19
Q3 2025	$27.48M	$-33,347,000	$-0.69

Earnings & Analyst Ratings

Next Earnings: Wed, Nov 4, 2026

Calendar →

Related Market News

No specific coverage for URGN yet. Check out our latest market news or earnings calendar.

Get URGN Alerts

Stay ahead with breaking news, price alerts, and expert analysis on UroGen Pharma Ltd. Ordinary Shares.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.